文献速递神经肿瘤

儿童、年轻成人及老年成人IDH突变型胶质瘤患者的比较分析

A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.
PubMed 文献 · Neuro Oncol · 2024-01-01

该多中心回顾性研究纳入2013至2019年379例IDH突变型2-4级胶质瘤患者,按年龄分为儿童(<19岁)、年轻成人(19-39岁)和老年成人(≥40岁)。年轻成人组无进展生存期和恶性转化时间显著短于儿童及老年成人组,但总生存期无显著差异。

要点

  • 年轻成人IDH突变型胶质瘤患者无进展生存期和恶性转化时间显著短于儿童及老年成人组。
  • 三组间总生存期无显著差异。
  • 星形细胞瘤中CDK4/6拷贝数扩增与更短的无进展生存期和总生存期相关。

核心结论

  • 年轻成人IDH突变型胶质瘤患者无进展生存期和恶性转化时间显著短于儿童及老年成人组,但总生存期无差异。
  • 治疗方案随年龄显著不同,需进一步研究作为可干预的年龄相关结局驱动因素。

研究设计与样本

  • 多中心回顾性年龄分层比较研究,收集2013至2019年合作机构IDH突变型2-4级胶质瘤患者的临床、组织学和测序数据。
  • 共纳入379例有临床数据的IDH突变型胶质瘤患者,其中年轻成人204例。
  • 按年龄分为儿童(<19岁)、年轻成人(19-39岁)和老年成人(≥40岁)。

主要发现

  • 379例患者中少突胶质细胞瘤155例(41%),星形细胞瘤224例(59%)。
  • 年轻成人组无进展生存期和恶性转化中位时间显著短于儿童及老年成人组,但总生存期无显著差异。
  • 多变量分析校正病理类型、切除范围和初始治疗后,年轻成人组仍为更短无进展生存期的独立预后因素。
  • 星形细胞瘤中CDK4/6拷贝数扩增与更短的无进展生存期和总生存期相关。
  • 少突胶质细胞瘤中PIK3CA和CDKN2A/2B改变与更短的总生存期相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The frequency and significance of IDH mutations in glioma across age groups are incompletely understood. We performed a multi-center retrospective age-stratified comparison of patients with IDH-mutant gliomas to identify age-specific differences in clinico-genomic features, treatments, and outcomes. METHODS: Clinical, histologic, and sequencing data from patients with IDH-mutant, grades 2-4 gliomas, were collected from collaborating institutions between 2013 and 2019. Patients were categorized as pediatric (<19 years), young adult (YA; 19-39 years), or older adult (≥40 years). Clinical presentation, treatment, histologic, and molecular features were compared across age categories using Fisher's exact test or analysis-of-variance. Cox proportional-hazards regression was used to determine the association of age and other covariates with overall (OS) and progression-free survival (PFS). RESULTS: We identified a cohort of 379 patients (204 YA) with IDH-mutant glioma with clinical data. There were 155 (41%) oligodendrogliomas and 224 (59%) astrocytomas. YA showed significantly shorter PFS and shorter median time-to-malignant transformation (MT) compared to pediatric and adult groups, but no significant OS difference. Adjusting for pathology type, extent of resection, and upfront therapy in multivariable analysis, the YA group was independently prognostic of shorter PFS than pediatric and adult groups. Among astrocytomas, CDK4/6 copy number amplifications were associated with both shorter PFS and shorter OS. Among oligodendrogliomas, PIK3CA and CDKN2A/2B alterations were associated with shorter OS. CONCLUSIONS: IDH-mutant glioma YA patients had significantly shorter PFS and time to MT but did not differ in OS compared to pediatric and adult groups. Treatment approaches varied significantly by patient age and warrant further study as addressable age-associated outcome drivers.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Lim-Fat MJ, Cotter JA, Touat M, et al. A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients. Neuro Oncol. 2024. PMID: 39082676. doi:10.1093/neuonc/noae142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。